Exploring sexual function in adrenal insufficiency: findings from the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent therapy in hypocortisolism (DREAM) trial.
adrenal insufficiency
dual‐release hydrocortisone
erectile dysfunction
sexual function
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
revised:
23
02
2024
received:
10
01
2024
accepted:
07
03
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
aheadofprint
Résumé
Data on sexual function in patients with adrenal insufficiency are scarce and largely controversial. To investigate sexual dysfunction in patients with primary and secondary adrenal insufficiency and the effects of switching to once-daily dual-release hydrocortisone on sexual function in outcome assessors blinded, randomized, multicenter, active comparator clinical trial. Eighty-nine adrenal insufficiency patients on conventional, multiple daily doses of glucocorticoid replacement, enrolled in the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent in hypocortisolism (DREAM) trial, were randomly assigned to continue their therapy or to switch to an equivalent dose of dual-release hydrocortisone. Sixty-three patients (34 women) consented to sex steroid measurements and questionnaires completion for quality of life (Addison's disease-specific quality-of-life questionnaire) and sexual function evaluation (female sexual function index for women, International Index of Erectile Function-Erectile Function for men) at baseline and 24 weeks after randomization. At baseline, sexual dysfunction was observed in 41% of women and 59% of men with adrenal insufficiency. In both sexes, no associations were found between sexual function and hormone levels, whereas Addison's disease-specific quality-of-life questionnaire total and fatigue domain scores positively correlated with total female sexual function index and International Index of Erectile Function-Erectile Function scores. At 24 weeks, there was no significant difference either in sexual function or sex steroid levels between study groups. In the dual-release hydrocortisone group, the variation in the female sexual function index desire domain score was positively associated with the change in Addison's disease-specific quality-of-life questionnaire's symptom domain score (ρ = 0.478, p = 0.045). Sexual dysfunction is common in adrenal insufficiency patients and is likely explained by multiple factors. dual-release hydrocortisone treatment is not directly associated with sexual function improvement, but an indirect effect mediated by quality-of-life amelioration cannot be excluded.
Sections du résumé
BACKGROUND
BACKGROUND
Data on sexual function in patients with adrenal insufficiency are scarce and largely controversial.
OBJECTIVES
OBJECTIVE
To investigate sexual dysfunction in patients with primary and secondary adrenal insufficiency and the effects of switching to once-daily dual-release hydrocortisone on sexual function in outcome assessors blinded, randomized, multicenter, active comparator clinical trial.
MATERIALS AND METHODS
METHODS
Eighty-nine adrenal insufficiency patients on conventional, multiple daily doses of glucocorticoid replacement, enrolled in the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent in hypocortisolism (DREAM) trial, were randomly assigned to continue their therapy or to switch to an equivalent dose of dual-release hydrocortisone. Sixty-three patients (34 women) consented to sex steroid measurements and questionnaires completion for quality of life (Addison's disease-specific quality-of-life questionnaire) and sexual function evaluation (female sexual function index for women, International Index of Erectile Function-Erectile Function for men) at baseline and 24 weeks after randomization.
RESULTS
RESULTS
At baseline, sexual dysfunction was observed in 41% of women and 59% of men with adrenal insufficiency. In both sexes, no associations were found between sexual function and hormone levels, whereas Addison's disease-specific quality-of-life questionnaire total and fatigue domain scores positively correlated with total female sexual function index and International Index of Erectile Function-Erectile Function scores. At 24 weeks, there was no significant difference either in sexual function or sex steroid levels between study groups. In the dual-release hydrocortisone group, the variation in the female sexual function index desire domain score was positively associated with the change in Addison's disease-specific quality-of-life questionnaire's symptom domain score (ρ = 0.478, p = 0.045).
DISCUSSION
CONCLUSIONS
Sexual dysfunction is common in adrenal insufficiency patients and is likely explained by multiple factors. dual-release hydrocortisone treatment is not directly associated with sexual function improvement, but an indirect effect mediated by quality-of-life amelioration cannot be excluded.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Union, National Recovery and Resilience Plan, Investment PE8 - Project Age-It: "Ageing Well in an Ageing Society"
ID : B53C22004090006
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca MIUR
ID : 2015ZTT5KB
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca MIUR
ID : RBAP109BLT
Informations de copyright
© 2024 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.
Références
Husebye ES, Pearce SH, Krone NP, Kampe O. Adrenal insufficiency. Lancet. 2021;397(10274):613‐629. doi:10.1016/S0140‐6736(21)00136‐7
Kumar R, Wassif WS. Adrenal insufficiency. J Clin Pathol. 2022;75(7):435‐442. doi:10.1136/jclinpath‐2021‐207895
Bergthorsdottir R, Leonsson‐Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population‐based study. J Clin Endocrinol Metab. 2006;91(12):4849‐4853. doi:10.1210/jc.2006‐0076
Ngaosuwan K, Johnston DG, Godsland IF, et al. Increased mortality risk in patients with primary and secondary adrenal insufficiency. J Clin Endocrinol Metab. 2021;106(7):e2759‐e2768. doi:10.1210/clinem/dgab096
Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3(3):216‐226. doi:10.1016/S2213‐8587(14)70142‐1
Bancos I, Hazeldine J, Chortis V, et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality. Eur J Endocrinol. 2017;176(4):471‐480. doi:10.1530/EJE‐16‐0969
Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid‐induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437‐447. doi:10.1038/s41574‐020‐0341‐0
Isidori AM, Venneri MA, Graziadio C, et al. Effect of once‐daily, modified‐release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single‐blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):173‐185. doi:10.1016/S2213‐8587(17)30398‐4
Lovas K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160(6):993‐1002. doi:10.1530/EJE‐08‐0880
Minnetti M, Hasenmajer V, Sbardella E, et al. Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool. Eur J Endocrinol. 2022;187(5):719‐731. doi:10.1530/EJE‐22‐0454
Borges R, Temido P, Sousa L, et al. Metabolic syndrome and sexual (dys)function. J Sex Med. 2009;6(11):2958‐2975. doi:10.1111/j.1743‐6109.2009.01412.x
Kromer J, Hummel T, Pietrowski D, et al. Influence of HLA on human partnership and sexual satisfaction. Sci Rep. 2016;6:32550. doi:10.1038/srep32550
Lorenz T, van Anders S. Interactions of sexual activity, gender, and depression with immunity. J Sex Med. 2014;11(4):966‐979. doi:10.1111/jsm.12111
Conrad N, Verbeke G, Molenberghs G, et al. Autoimmune diseases and cardiovascular risk: a population‐based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022;400(10354):733‐743. doi:10.1016/S0140‐6736(22)01349‐6
Johannsson G, Ragnarsson O. Cardiovascular and metabolic impact of glucocorticoid replacement therapy. Front Horm Res. 2014;43:33‐44. doi:10.1159/000360556
Reato G, Morlin L, Chen S, et al. Premature ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab. 2011;96(8):E1255‐E1261. doi:10.1210/jc.2011‐0414
Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B, Quinkler M. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol. 2008;159(6):811‐817. doi:10.1530/EJE‐08‐0578
Alemany M. The roles of androgens in humans: biology, metabolic regulation and health. Int J Mol Sci. 2022;23(19):11952. doi:10.3390/ijms231911952
Vogt EC, Breivik L, Royrvik EC, Grytaas M, Husebye ES, Oksnes M. Primary ovarian insufficiency in women with Addison's disease. J Clin Endocrinol Metab. 2021;106(7):e2656‐e2663. doi:10.1210/clinem/dgab140
Erichsen MM, Husebye ES, Michelsen TM, Dahl AA, Lovas K. Sexuality and fertility in women with Addison's disease. J Clin Endocrinol Metab. 2010;95(9):4354‐4360. doi:10.1210/jc.2010‐0445
Zamponi V, Lardo P, Maggio R, et al. Female sexual dysfunction in primary adrenal insufficiency. J Clin Med. 2021;10(13):2767. doi:10.3390/jcm10132767
Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta‐analysis of randomized placebo‐controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(10):3676‐3681. doi:10.1210/jc.2009‐0672
van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin‐like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo‐controlled, cross‐over trial. J Clin Endocrinol Metab. 2005;90(6):3295‐3303. doi:10.1210/jc.2004‐1802
Granata A, Tirabassi G, Pugni V, et al. Sexual dysfunctions in men affected by autoimmune Addison's disease before and after short‐term gluco‐ and mineralocorticoid replacement therapy. J Sex Med. 2013;10(8):2036‐2043. doi:10.1111/j.1743‐6109.2012.02673.x
Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure‐time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual‐release formulation. J Clin Endocrinol Metab. 2012;97(2):473‐481. doi:10.1210/jc.2011‐1926
Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, Oksnes M. Modified‐release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol. 2015;172(5):619‐626. doi:10.1530/EJE‐14‐1114
Rowland DL, McNabney SM, Mann AR. Sexual function, obesity, and weight loss in men and women. Sex Med Rev. 2017;5(3):323‐338. doi:10.1016/j.sxmr.2017.03.006
Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self‐report instrument for the assessment of female sexual function. Journal of sex & marital therapy. 2000;26(2):191‐208. doi:10.1080/009262300278597
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross‐validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1‐20. doi:10.1080/00926230590475206
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822‐830.
Iannone M, Dima AP, Sciarra F, Botre F, Isidori AM. Development and validation of a liquid chromatography‐tandem mass spectrometry method for the simultaneous analysis of androgens, estrogens, glucocorticoids and progestagens in human serum. Biomed Chromatogr. 2022;36(5):e5344. doi:10.1002/bmc.5344
Oksnes M, Bensing S, Hulting AL, et al. Quality of life in European patients with Addison's disease: validity of the disease‐specific questionnaire AddiQoL. J Clin Endocrinol Metab. 2012;97(2):568‐576. doi:10.1210/jc.2011‐1901
Taylor JZ, Lewis CL, Davis LE. Sexual wellness and rare disease considerations: a behavioral case conceptualization and approach to counseling treatment. JCSSW. 2019;1(2). doi:10.34296/01021018
Vistad I, Fossa SD, Kristensen GB, Mykletun A, Dahl AA. The sexual activity questionnaire: psychometric properties and normative data in a Norwegian population sample. J Womens Health. 2007;16(1):139‐148. doi:10.1089/jwh.2006.0052
Lonnee‐Hoffmann RA, Dennerstein L, Lehert P, Szoeke C. Sexual function in the late postmenopause: a decade of follow‐up in a population‐based cohort of Australian women. J Sex Med. 2014;11(8):2029‐2038. doi:10.1111/jsm.12590
McCool ME, Zuelke A, Theurich MA, Knuettel H, Ricci C, Apfelbacher C. Prevalence of female sexual dysfunction among premenopausal women: a systematic review and meta‐analysis of observational studies. Sex Med Rev. 2016;4(3):197‐212. doi:10.1016/j.sxmr.2016.03.002
Gerstenberger EP, Rosen RC, Brewer JV, et al. Sexual desire and the female sexual function index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med. 2010;7(9):3096‐3103. doi:10.1111/j.1743‐6109.2010.01871.x
Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003. doi:10.1038/nrdp.2016.3
Lewis RW, Fugl‐Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7:1598‐1607. Pt 2. doi:10.1111/j.1743‐6109.2010.01778.x
McCabe MP, Sharlip ID, Lewis R, et al. Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13(2):144‐152. doi:10.1016/j.jsxm.2015.12.034
Corona G, Cucinotta D, Di Lorenzo G, et al. The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction. J Endocrinol Invest. 2023;46(6):1241‐1274. doi:10.1007/s40618‐023‐02015‐5
Corona G, Rastrelli G, Isidori AM, et al. Erectile dysfunction and cardiovascular risk: a review of current findings. Expert Rev Cardiovasc Ther. 2020;18(3):155‐164. doi:10.1080/14779072.2020.1745632
Defeudis G, Mazzilli R, Tenuta M, et al. Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2022;38(2):e3494. doi:10.1002/dmrr.3494
Isidori AM, Aversa A, Calogero A, et al. Adult‐ and late‐onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE). J Endocrinol Invest. 2022;45(12):2385‐2403. doi:10.1007/s40618‐022‐01859‐7
MacDonald SM, Burnett AL. Physiology of erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2021;48(4):513‐525. doi:10.1016/j.ucl.2021.06.009
Corona G, Rastrelli G, Filippi S, Vignozzi L, Mannucci E, Maggi M. Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl. 2014;16(4):581‐591. doi:10.4103/1008‐682X.126386
Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341(14):1013‐1020. doi:10.1056/NEJM199909303411401
Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen‐deficient women: a placebo‐controlled trial. J Clin Endocrinol Metab. 2002;87(5):2046‐2052. doi:10.1210/jcem.87.5.8494
Gurnell EM, Hunt PJ, Curran SE, et al. Long‐term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93(2):400‐409. doi:10.1210/jc.2007‐1134
Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000;85(12):4650‐4656. doi:10.1210/jcem.85.12.7022
Lovas K, Gebre‐Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9‐month, randomized, parallel group clinical trial. J Clin Endocrinol Metab. 2003;88(3):1112‐1118. doi:10.1210/jc.2002‐020769
Maseroli E, Vignozzi L. Are endogenous androgens linked to female sexual function? A systemic review and meta‐analysis. J Sex Med. 2022;19(4):553‐568. doi:10.1016/j.jsxm.2022.01.515
Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489‐3510. doi:10.1210/jc.2014‐2260
Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660‐4666. doi:10.1210/jc.2019‐01603
Methlie P, Hustad SS, Kellmann R, et al. Multisteroid LC‐MS/MS assay for glucocorticoids and androgens, and its application in Addison's disease. Endocr Connect. 2013;2(3):125‐136. doi:10.1530/EC‐13‐0023
De Alcubierre D, Ferrari D, Mauro G, Isidori AM, Tomlinson JW, Pofi R. Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations. J Endocrinol Invest. 2023;46(10):1961‐1982. doi:10.1007/s40618‐023‐02091‐7
Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res. 2006;18(3):236‐250. doi:10.1038/sj.ijir.3901410
Limoncin E, Lotti F, Rossi M, et al. The impact of premature ejaculation on the subjective perception of orgasmic intensity: validation and standardisation of the ‘Orgasmometer. Andrology. 2016;4(5):921‐926. doi:10.1111/andr.12220
Mollaioli D, Di Sante S, Limoncin E, et al. Validation of a Visual Analogue Scale to measure the subjective perception of orgasmic intensity in females: the Orgasmometer‐F. PLoS One. 2018;13(8):e0202076. doi:10.1371/journal.pone.0202076